• 1
    Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm. Bowel Dis. 2005; 11: S3S12.
  • 2
    Allison MC, Dhillon AP, Lewis WG, eds. Inflammatory Bowel Disease. London: Mosby, 1998; 995.
  • 3
    Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr. Pharm. Des. 2003; 9: 30721.
  • 4
    Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apher. 2001; 16: 19.
  • 5
    Fukuda Y, Matsui T, Suzuki Y et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J. Gastroenterol. 2004; 39: 115864.
  • 6
    Sawada K, Ohnishi K, Fukui S et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J. Gastroenterol. 1995; 30: 3229.
  • 7
    Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther. Apher. Dial. 2003; 7: 447.
  • 8
    Saniabadi AR, Hanai H, Suzuki Y et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J. Clin. Apher. 2005; 20: 17184.
  • 9
    Hiraishi K, Takeda Y, Shiobara N et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial. 2003; 7: 33440.
  • 10
    D'Arrigo C, Candal-Couto JJ, Greer M et al. Human neutrophil Fc receptor-mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin. Exp. Immunol. 1993; 100: 1739.
  • 11
    Sakuraba A, Motoya S, Watanabe K et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am. J. Gastroenterol. 2009; 104: 29905.
  • 12
    Sands BE, Sandborn WJ, Feagan B et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 4009.
  • 13
    Kosaka T, Sawada K, Ohnishi K et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern. Med. 1999; 38: 10211.
  • 14
    Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am. J. Gastroenterol. 2003; 98: 51112.
  • 15
    Kusaka T, Fukunaga K, Ohnishi K et al. Adsorptive monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease. J. Clin. Apher. 2004; 19: 16873.
  • 16
    Matsumoto T, Andoh A, Okawa K et al. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther. Apher. Dial. 2008; 12: 48490.
  • 17
    Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther. Apher. 1998; 2: 10914.
  • 18
    Hanai H, Iida T, Takeuchi K et al. Decrease of reactive-oxygen –producing garnulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J. Gastroenterol. 2005; 11: 308590.
  • 19
    Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001; 182: 1832.
  • 20
    Kosaka T, Sawada K, Ohnishi K et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Expert Opin. Biol. Ther. 2005; 5: 45162.
  • 21
    Andoh A, Tsujikawa T, Inatomi O et al. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Ther. Apher. Dial. 2005; 9: 2706.
  • 22
    Kanai T, Makita S, Kawamura T et al. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm. Bowel Dis. 2007; 13: 28490.
  • 23
    Hanai H, Iida T, Takeuchi K et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2008; 103: 121016.
    Direct Link:
  • 24
    Danese S, Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 2004; 99: 93845.
    Direct Link:
  • 25
    Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand. J. Gastroenterol. 1973; 8: 1358.
  • 26
    Harries AD, Fitzsimons E, Fifield R, Dew MJ, Rhoades J. Platelet count: a simple measure of activity in Crohn's disease. Br. Med. J. 1983; 286: 1476.
  • 27
    Fukunaga K, Fukuda Y, Yokoyama Y et al. Activated platelet as a possible early marker to predict clinical efficacy of Leukocytapheresis in severe ulcerative colitis patients. J. Gastroenterol. 2006; 41: 52432.
  • 28
    Kanke K, Nakano M, Hiraishi H et al. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis. 2004; 36: 51218.
  • 29
    Naganuma M, Funakoshi S, Sakuraba A et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. 2004; 10: 2517.
  • 30
    Yamamoto T, Umegae S, Kitagawa T et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. 2004; 20: 78392.
  • 31
    Domenech E, Hinojosa J, Esteve-Comas M et al. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. 2004; 20: 134752.
  • 32
    Passalacqua S, Ferraro PM, Bresci G et al. The Italian registry of therapeutic apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J. Clin. Apher. 2011; 26: 3327.
  • 33
    Sakata Y, Iwakiri R, Amemori S et al. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur. J. Gastroenterol. Hepatol. 2008; 20: 62933.
  • 34
    Saniabadi AR, Hanai H, Lofberg R et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. 2003; 7: 4859.
  • 35
    Hanai H, Watanabe F, Takeuchi K et al. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin. Gastroenterol. Hepatol. 2003; 1: 2835.
  • 36
    McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin. Exp. Immunol. 1991; 86: 48993.
  • 37
    Rugtveit J, Brandtzaeg P, Halstensen TS et al. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994; 35: 66974.
  • 38
    Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978; 74: 5013.
  • 39
    Brannigan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000; 13: 3616.
  • 40
    Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 1995; 16: 216.
  • 41
    Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998; 42: 4706.
  • 42
    Tibble JA, Sigthorsson G, Bridger D et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 1522.
  • 43
    Limburg P, David M, Ahlquist A, Sandborn WJ. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am. J. Gastroenterol. 2000; 95: 28317.
    Direct Link:
  • 44
    Yokoyama Y, Fukunaga K, Fukuda Y et al. Demonstration of low CD25High+CD4+ and high CD28-CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective leucocytapheresis. Dig. Dis. Sci. 2007; 52: 272531.
  • 45
    Kamikozuru K, Fukunaga K, Hirota S et al. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin. Exp. Immunol. 2009; 156: 3207.
  • 46
    Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dis. Sci. 2002; 6: 133441.
  • 47
    Andoh A, Tsujikawa T, Inatomi O et al. Suppression of inflammatory cytokines secretion by granulocyte/monocytes adsorptive apheresis in active ulcerative colitis. Ther. Apher. Dial. 2005; 2: 1237.
  • 48
    Yoshino T, Nakase H, Matsuura M et al. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011; 84: 39.
  • 49
    Fukunaga K, Kamikozuru K, Yokoyama Y et al. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis. J. Clin. Apher. 2011; 26: 32631.
  • 50
    Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey; Final Report of Findings. Cited 22 Mar 2011. Available from URL:
  • 51
    Ministry of Health, Labor and Welfare. Annual Report of the Survey for Health and Nutrition in the Citizen 2009. [Japanese]. Cited 22 Mar 2011. Available from URL:
  • 52
    Kikuyama R, Fukunaga K, Kawai M et al. Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis. Ther. Apher. Dial. 2011; 15: 3606.
  • 53
    Yoshimura N, Tadami T, Kawaguchi T et al. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J. Gastroenterol. 2011; 47: 4955.
  • 54
    Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol. Ther. 2003; 18: 17581.
  • 55
    Fukunaga K, Yokoyama Y, Kamikozuru K et al. A prospective randomized double blind sham controlled trial to assess the efficacy of monthly Granulocyte/ Monocyte adsorption Apheresis as maintenance therapy for patients with steroid refractory ulcerative colitis. Gut 2010; 59 (Suppl. III): A73.
  • 56
    Fukunaga K, Yokoyama Y, Kamikozuru K et al. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J. Clin. Apher. 2010; 25: 2268.